{"id":12145,"date":"2026-05-28T01:30:00","date_gmt":"2026-05-27T23:30:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=52643204b3e40dbe158fd7d926942557"},"modified":"2026-05-28T01:30:00","modified_gmt":"2026-05-27T23:30:00","slug":"diamedica-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-2026","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=12145","title":{"rendered":"DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026"},"content":{"rendered":"<p>MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held in New York on June 2-4 2026.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260527840935\/en\/2816434\/5\/DiaMedica-Logo-white-background.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260527840935\/en\/2816434\/22\/DiaMedica-Logo-white-background.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260527840935\/en\/2816434\/5\/DiaMedica-Logo-white-background.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260527840935\/en\/2816434\/21\/DiaMedica-Logo-white-background.jpg\" \/><\/a><p>\n<b>Jefferies Global Healthcare Conference<\/b><\/p><p class=\"bwmarginl1\">\n<b>Date: <\/b>Thursday, June 4, 2026\n<br\/><b>Time:<\/b> 3:45 PM ET\n<br\/><b>Format: <\/b>Corporate Presentation<\/p><p>\nIf you are interested in arranging a 1\u00d71 meeting with management, please contact your conference representative.<\/p><p>\n<b><i>About DiaMedica Therapeutics Inc.<\/i><\/b><\/p><p>\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. DiaMedica\u2019s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company\u2019s website at <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.diamedica.com&amp;esheet=54542834&amp;newsitemid=20260527840935&amp;lan=en-US&amp;anchor=www.diamedica.com&amp;index=1&amp;md5=cf8faf48574cad5e0df0fa3b35a7423e\" rel=\"nofollow\" shape=\"rect\">www.diamedica.com<\/a>.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nScott Kellen\n<br\/>Chief Financial Officer\n<br\/>Phone: (763) 496-5118\n<br\/><a  href=\"mailto:skellen@diamedica.com\" rel=\"nofollow\" shape=\"rect\">skellen@diamedica.com<\/a><\/p><p>\n<b>For Investor Inquiries:<\/b><br\/>Mike Moyer\n<br\/>Managing Director, LifeSci Advisors, LLC\n<br\/>Phone: (617) 308-4306\n<br\/><a  href=\"mailto:mmoyer@lifesciadvisors.com\" rel=\"nofollow\" shape=\"rect\">mmoyer@lifesciadvisors.com<\/a><\/p><p>\n<b>Media Contact:<\/b><br\/>Madelin Hawtin\n<br\/>LifeSci Communications\n<br\/><a  href=\"mailto:mhawtin@lifescicomms.com\" rel=\"nofollow\" shape=\"rect\">mhawtin@lifescicomms.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211;DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Compan&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-12145","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12145"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12145\/revisions"}],"predecessor-version":[{"id":12146,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12145\/revisions\/12146"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}